Journal article · 2017

Looking Beyond Overall Survival in Ovarian Cancer Clinical Trials

Catlin Nalley

Oncology Times, 39(23), 34 · Published 28 November 2017 · DOI 10.1097/01.cot.0000527893.21568.7c

View at the publisherCite this paper

In brief

“Looking Beyond Overall Survival in Ovarian Cancer Clinical Trials” is a 2017 journal article by Catlin Nalley, published in Oncology Times. OpenAlex counts 0 citations as of 22 November 2026. The publisher's version is not open access, and OpenAlex records no free legal copy.

Citations
0
Authors
1

Abstract

ovarian cancer; clinical trials: ovarian cancer; clinical trialsNEW YORK CITY—Historically, overall survival (OS) has been considered the primary endpoint in randomized clinical trials of ovarian cancer. This focus was justified by the toxicity of available regimens, the marginal survival benefit of subsequent therapies (second-line and beyond), and the belief that ovarian cancer for the most… Read the full abstract at the publisher.

Excerpt. This paper is not open access.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Nalley, C. (2017). Looking Beyond Overall Survival in Ovarian Cancer Clinical Trials. Oncology Times, 39(23), 34. https://doi.org/10.1097/01.cot.0000527893.21568.7c

MLA 9

Nalley, Catlin. “Looking Beyond Overall Survival in Ovarian Cancer Clinical Trials.” Oncology Times, vol. 39, no. 23, 2017, p. 34. https://doi.org/10.1097/01.cot.0000527893.21568.7c.

Chicago

Nalley, Catlin. 2017. “Looking Beyond Overall Survival in Ovarian Cancer Clinical Trials.” Oncology Times 39 (23): 34. https://doi.org/10.1097/01.cot.0000527893.21568.7c.

Harvard

Nalley, C. (2017) ‘Looking Beyond Overall Survival in Ovarian Cancer Clinical Trials’, Oncology Times, 39(23), p. 34. doi:10.1097/01.cot.0000527893.21568.7c.

IEEE

C. Nalley, “Looking Beyond Overall Survival in Ovarian Cancer Clinical Trials,” Oncology Times, vol. 39, no. 23, p. 34, 2017, doi: 10.1097/01.cot.0000527893.21568.7c.

BibTeX

@article{nalley2017looking,
  title     = {{Looking Beyond Overall Survival in Ovarian Cancer Clinical Trials}},
  author    = {Nalley, Catlin},
  journal   = {Oncology Times},
  year      = {2017},
  volume    = {39},
  number    = {23},
  pages     = {34},
  doi       = {10.1097/01.cot.0000527893.21568.7c},
  url       = {https://doi.org/10.1097/01.cot.0000527893.21568.7c}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment

  • ovarian cancer
  • clinical trial endpoints
  • overall survival
  • progression-free survival
  • second-line therapy
  • third-line therapy
  • fourth-line therapy
  • treatment toxicity

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Nalley, C. (2017). Looking Beyond Overall Survival in Ovarian Cancer Clinical Trials. Oncology Times, 39(23), 34. https://doi.org/10.1097/01.cot.0000527893.21568.7c

How many times has this paper been cited?

0 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.

Who wrote this paper?

Catlin Nalley.

What is the DOI of this paper?

10.1097/01.cot.0000527893.21568.7c, permanently at https://doi.org/10.1097/01.cot.0000527893.21568.7c. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.